ISRCTN38366450已完成不适用
A multicentre, randomised, double-blind, placebo-controlled trial to evaluate intravenous infusion of salbutamol versus saline for 28-day mortality in patients with acute respiratory distress syndrome
Heart of England NHS Foundation Trust (UK)0 个研究点目标入组 100 人开始时间: 2006年7月7日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •On day 1 following intensive care unit (ICU) admission, the primary caring ICU clinician should consider all adult patients (age =18 years) with severe hypoxaemic respiratory failure (PaO2/FiO2) =26.7 kPa to be eligible for inclusion in the trial
排除标准
- •1. Pregnancy
- •2. Cardiogenic pulmonary oedema (confirmed by medical history and chest x-ray)
- •3. Severe obstructive airway disease requiring nebulised or intravenous (IV) beta 2-agonists
- •4. Treatment with beta 2-blockers =48 hours
- •5. Brain stem death
- •6. Treatment withdrawal =24 hours, which indicates any interventions (including a trial) would be considered inappropriate
- •7. Refusing consent or patients in whom relatives refuse assent
- •8. Enrolled in another interventional clinical trial in the last 28 days
研究者
相似试验
进行中（未招募）
不适用
A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalised for volume overload and require intravenous diuretic therapy. - PROTECT {CKI-302}Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.MedDRA version: 9.1Level: LLTClassification code 10000803Term: Acute heart failureEUCTR2006-001637-18-SEovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)1,000
进行中（未招募）
不适用
A research study of a new drug (MT-102) for patients with weight loss and weakness (cachexia) related to lung or colorectal cancerCachexia related to stage III and IV non-small cell lung cancer and colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10064015Term: Cancer cachexiaSystem Organ Class: 100000004861EUCTR2010-022486-10-DEPsioxus Therapeutics Limited129
进行中（未招募）
不适用
A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures.EUCTR2004-000369-37-DKGlaxoSmithKline Group of Companies411
进行中（未招募）
1 期
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day), with open-label extension, in adults with attention deficit/ hyperactivity disorder. - LAMDAAttention Deficit Hyperactivity Disorder (ADHD)Classification code 10003731EUCTR2004-000730-37-CZJanssen-Cilag Medical Affairs EMEA
进行中（未招募）
1 期
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose ranging study to determine the effect of mepolizumab on exacerbation rates in subjects with severe uncontrolled refractory asthma.EUCTR2009-014415-12-GBGlaxoSmithKline Research & Development Ltd